• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

    4/9/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHIO alert in real time by email

    -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentration

    Marlborough, Massachusetts--(Newsfile Corp. - April 9, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in Phio's Phase 1b clinical trial (NCT 06014086) for Phio's lead product candidate, PH-762.

    Phio's Phase 1b clinical trial is a multi-center, dose-escalating trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This trial assesses the tumor response and determines the recommended dose for further study of PH-762. In the third cohort of this trial, three patients with cutaneous squamous cell carcinoma were enrolled. For these patients, injections were well tolerated with no serious adverse events and there were no dose-limiting toxicities. Pathology results related to efficacy of PH-762 in the third cohort are forthcoming.

    "We are impressed with the continuing safety profile of PH-762 having now progressed through the first 3 escalating doses," said Mary Spellman, MD, Phio's acting Chief Medical Officer.

    Previously, seven patients diagnosed with cutaneous carcinomas were treated in dose cohorts 1 and 2. The second cohort enrolled a total of 4 patients who were diagnosed with cutaneous squamous cell carcinoma. At Day 36 (tumor excision) in the second cohort, two patients had a complete response (100% tumor clearance), and one patient had a partial response (90% clearance). All three patients in cohort 1 and one patient in cohort 2 maintained stable disease.

    "We are optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer," said Robert Bitterman, President and CEO of Phio Pharmaceuticals.

    About Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The on-going Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.

    For additional information, visit the Company's website, www.phiopharma.com.

       Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-Looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells and statements regarding our commercial and clinical strategy, development plans and timelines and other future events.  

     These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.  Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.  

    Contact:
    Phio Pharmaceuticals Corp. 
    Jennifer Phillips: [email protected]  
    Corporate Affairs  

    Corporate Logo

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247877

    Get the next $PHIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PHIO

    DatePrice TargetRatingAnalyst
    6/5/2025$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $PHIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

      -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. - June 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in its Phase 1b clinical trial designed to evaluate the safety and tolerability of intratumoral (IT) PH-762 in the treatment of Stages 1, 2, and 4 cutaneous squamous cell carcinoma (cSCC), Stage 4 m

      6/25/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

      Registration Link for Presentation and live Q&A to take place, Monday, June 30, 2025 at 10:00 am ESTMarlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were rep

      6/24/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

      Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ETMarlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Mr. Bitterman will also host one-on-one meetings with investors at the conferen

      5/19/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    SEC Filings

    See more
    • Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      6/25/25 8:46:08 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      6/12/25 7:49:03 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Phio Pharmaceuticals Corp.

      10-Q - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      5/15/25 4:34:57 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Carson Lisa Cabott

      3 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/18/25 4:30:56 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/25 5:00:01 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ferrara Robert L bought $6,050 worth of shares (2,500 units at $2.42), increasing direct ownership by 19% to 15,666 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/25 4:59:45 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Phio Pharmaceuticals with a new price target

      H.C. Wainwright resumed coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $14.00

      6/5/25 7:35:43 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Phio Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

      6/14/21 6:22:20 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/25 5:00:01 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ferrara Robert L bought $6,050 worth of shares (2,500 units at $2.42), increasing direct ownership by 19% to 15,666 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/25 4:59:45 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman, Pres & CEO Bitterman Robert J bought $4,125 worth of shares (1,500 units at $2.75), increasing direct ownership by 6% to 25,149 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/10/25 4:43:57 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

      Registration Link for Presentation and live Q&A to take place, Monday, June 30, 2025 at 10:00 am ESTMarlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were rep

      6/24/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

      Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio's presentation and live Q&A will take place on Wednesday, May

      5/1/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

      Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following the appointment of Mr. Deming, the Board now comprises 6 directors, 5 of whom are independent."Mr. Deming's extensive experience in in the biopharma sector, both through his investme

      2/20/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp.

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      11/13/24 11:20:45 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      2/6/24 10:30:10 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      2/8/23 6:07:04 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care